Chemoprevention of Head & Neck Cancer
Chemoprevention of Head & Neck Cancer
批准号:
8930348
负责人:
Daniel E Johnson
金额:
$29.26万
依托单位国家:
美国
项目类别:
财政年份:
2004
资助国家:
美国
项目状态:
已结题
起止时间:
2004-07-01 至 2020-06-30
关键词:
Air PollutionAldehydesAmendmentAntioxidantsBenzeneBindingBiological AssayBiological MarkersBrassicaBroccoli - dietaryCarcinogensCell LineCell NucleusChemopreventionChemopreventive AgentChronicClinicalClinical ResearchClinical TrialsDevelopmentDietDiseaseDoseDrug KineticsEnvironmental CarcinogensEnzymesEpidemiologic StudiesEpithelialExposure toFamilyFoundationsGene ExpressionGene TargetingGenesGoalsHead and Neck CancerHead and Neck Squamous Cell CarcinomaHumanHuman PapillomavirusImmunityIn VitroInterventionLaboratoriesMalignant Epithelial CellMalignant NeoplasmsMalignant Squamous Cell NeoplasmMasticationMucous MembraneMusMyrosinaseNeoplasm MetastasisNitrosaminesOncogenicOralOral mucous membrane structurePathway interactionsPatientsPharmacodynamicsPhasePhase II/III TrialPhytochemicalPlantsPolyubiquitinationPredispositionPreparationPreventionPrimary NeoplasmPromoter RegionsProtein DephosphorylationProteinsQuality of lifeRandomizedRelative (related person)ReportingResponse ElementsRiskSTAT3 geneSafetySecond Primary CancersSeedsSignal PathwaySpecimenSulforaphaneTestingTimeTobaccoTobacco smokeTranscriptUp-Regulationcancer chemopreventioncigarette smokingcruciferous vegetabledetoxicationfood preparationglucoraphaninhealthy volunteerhigh riskkeratinocytemalignant mouth neoplasmmortalitymouse modeloral cavity epitheliumpreclinical studypreventresponsesmoking cessationsuccesstranscription factor
中文摘要
项目摘要-项目1
英文摘要
Project Summary - Project 1
Long-term success in the treatment of tobacco-related head and neck squamous cell carcinoma (HNSCC) is
hindered by an alarming rate of second primary tumor (SPT) development following curative treatment.
Patients with human papillomavirus (HPV)-negative HNSCC develop a SPT of the upper aerodigestive tract at
the rate of 3-6% per year, and are most likely to succumb to these secondary cancers. Although smoking
cessation reduces the occurrence of SPTs, moderation of risk is not observed for 5 years, and is insufficient to
return risk to baseline. The availability of a well-tolerated and affordable intervention that prevents SPTs would
have a major global impact on mortality and quality of life in patients at risk. Unfortunately, no tolerable and
effective chemopreventive agents have been identified for HNSCC. Our broad, long-term goal is the rigorous
translational development of a tolerable and effective chemoprevention strategy against HNSCC SPTs.
Reduced risk for HNSCC and SPTs is associated with diets rich in the Brassica family of cruciferous
vegetables, including broccoli. Broccoli is rich in glucoraphanin, which is metabolized to the key bioactive
component sulforaphane (SF). SF induces the expression of the transcription factor NRF2, which leads to
upregulation of NRF2 target genes. A number of NRF2 target genes encode cytoprotective enzymes, which
act to detoxify environmental carcinogens including benzene, aldehydes and nitrosamines found in tobacco
smoke. The relevance of the NRF2 signaling pathway for oral cancer chemoprevention is highlighted by the
enhanced susceptibility of mice lacking the Nrf2 gene to oral cancer induced by the carcinogen 4NQO. We are
developing broccoli seed preparations (BSPs) as a chemopreventive agent against carcinogen-induced
cancers, and have determined the safety, tolerability, and pharmacokinetics of BSPs in humans. We have also
shown that SF induces NRF2 and NRF2 target gene expression in normal oral keratinocytes and in HNSCC
cell lines. Moreover, we have provided first-time demonstration that transcripts for NRF2 target genes are
upregulated in the oral mucosa of healthy volunteers treated with SF-rich BSP. We hypothesize that NRF2
pathway activation in oral epithelium can be induced by administering BSP to patients curatively treated for a
first tobacco-related HNSCC, and that the target level of NRF2 pathway activation for chemopreventive
efficacy in humans can be determined in a mouse model of carcinogen-induced HNSCC. To test this
hypothesis we propose two Specific Aims: 1) To investigate the dose-response relationship between
sulforaphane (SF) and chemopreventive efficacy in a mouse model of carcinogen-induced HNSCC, and 2) To
systematically assess the clinical chemopreventive potential of BSP administration to patients with tobacco-
related HNSCC at high risk for SPT.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Implications of Procaspase-8 Mutations in Oral Squamous Cell Carcinoma
-
批准号:9198543
-
项目类别:
-
资助金额:$39.83万
-
财政年份:2016
-
负责人:Daniel E Johnson
-
依托单位:
Molecular Targeting Strategies in HNSCC
-
批准号:7982219
-
项目类别:
-
资助金额:$31.44万
-
财政年份:2010
-
负责人:Daniel E Johnson
-
依托单位:
Molecular Targeting Strategies in HNSCC
-
批准号:8465132
-
项目类别:
-
资助金额:$28.66万
-
财政年份:2010
-
负责人:Daniel E Johnson
-
依托单位:
Molecular Targeting Strategies in HNSCC
-
批准号:8091337
-
项目类别:
-
资助金额:$30.49万
-
财政年份:2010
-
负责人:Daniel E Johnson
-
依托单位:
Molecular Targeting Strategies in HNSCC
-
批准号:8658292
-
项目类别:
-
资助金额:$29.58万
-
财政年份:2010
-
负责人:Daniel E Johnson
-
依托单位:
Molecular Targeting Strategies in HNSCC
-
批准号:8259089
-
项目类别:
-
资助金额:$30.49万
-
财政年份:2010
-
负责人:Daniel E Johnson
-
依托单位:
EXERCISE REHABILITATION FOR THE OLDER CANCER PATIENT
-
批准号:7377810
-
项目类别:
-
资助金额:$4.55万
-
财政年份:2006
-
负责人:Daniel E Johnson
-
依托单位:
Opposing Roles for MEK/ERK in Differentiation & Leukemia
-
批准号:7414012
-
项目类别:
-
资助金额:$25.0万
-
财政年份:2005
-
负责人:Daniel E Johnson
-
依托单位:
Opposing Roles for MEK/ERK in Differentiation & Leukemia
-
批准号:7496745
-
项目类别:
-
资助金额:$3.87万
-
财政年份:2005
-
负责人:Daniel E Johnson
-
依托单位:
EXERCISE REHABILITATION FOR THE OLDER CANCER PATIENT
-
批准号:7200590
-
项目类别:
-
资助金额:$0.06万
-
财政年份:2005
-
负责人:Daniel E Johnson
-
依托单位:
Opposing Roles for MEK/ERK in Differentiation & Leukemia
-
批准号:7690576
-
项目类别:
-
资助金额:$4.19万
-
财政年份:2005
-
负责人:Daniel E Johnson
-
依托单位:
Opposing Roles for MEK/ERK in Differentiation & Leukemia
-
批准号:7614467
-
项目类别:
-
资助金额:$25.0万
-
财政年份:2005
-
负责人:Daniel E Johnson
-
依托单位:
Opposing Roles for MEK/ERK in Differentiation & Leukemia
-
批准号:7233226
-
项目类别:
-
资助金额:$25.0万
-
财政年份:2005
-
负责人:Daniel E Johnson
-
依托单位:
Opposing Roles for MEK/ERK in Differentiation & Leukemia
-
批准号:7083744
-
项目类别:
-
资助金额:$25.74万
-
财政年份:2005
-
负责人:Daniel E Johnson
-
依托单位:
Opposing Roles for MEK/ERK in Differentiation & Leukemia
-
批准号:6989364
-
项目类别:
-
资助金额:$26.36万
-
财政年份:2005
-
负责人:Daniel E Johnson
-
依托单位:
INHIBITION OF THE STATS SIGNALING NETWORK
-
批准号:8380696
-
项目类别:
-
资助金额:$20.1万
-
财政年份:2004
-
负责人:Daniel E Johnson
-
依托单位:
INHIBITION OF THE STATS SIGNALING NETWORK
-
批准号:8322145
-
项目类别:
-
资助金额:$20.49万
-
财政年份:2004
-
负责人:Daniel E Johnson
-
依托单位:
INHIBITION OF THE STATS SIGNALING NETWORK
-
批准号:8707195
-
项目类别:
-
资助金额:$18.65万
-
财政年份:2004
-
负责人:Daniel E Johnson
-
依托单位:
INHIBITION OF THE STATS SIGNALING NETWORK
-
批准号:7893350
-
项目类别:
-
资助金额:$22.9万
-
财政年份:2004
-
负责人:Daniel E Johnson
-
依托单位:
INHIBITION OF THE STATS SIGNALING NETWORK
-
批准号:8541586
-
项目类别:
-
资助金额:$29.18万
-
财政年份:2004
-
负责人:Daniel E Johnson
-
依托单位:
海外基金